Accelerating Early Access to Immunotherapies for Advanced Urothelial Carcinoma

Within one year, five immunotherapies have been approved for the treatment of patients with locally advanced or metastatic urothelial cancer. The availability of these immunotherapies brings challenges to all stakeholders in the field. Additional research is needed to identify biomarkers that are pr...

Full description

Saved in:

Bibliographic Details
Published in:	The oncologist (Dayton, Ohio) Vol. 23; no. 2; pp. 139 - 142
Main Authors:	Ning, Yang‐Min, Maher, V. Ellen, Beaver, Julia A., Goldberg, Kirsten B., Blumenthal, Gideon M., Pazdur, Richard
Format:	Journal Article
Language:	English
Published:	United States AlphaMed Press 01-02-2018
Subjects:	Health Services Accessibility Humans Immunotherapy Prognosis Urologic Neoplasms - immunology Urologic Neoplasms - therapy
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	Within one year, five immunotherapies have been approved for the treatment of patients with locally advanced or metastatic urothelial cancer. The availability of these immunotherapies brings challenges to all stakeholders in the field. Additional research is needed to identify biomarkers that are predictive of individual patient response to different immunotherapies.
Bibliography:	. Disclosures of potential conflicts of interest may be found at the end of this article SourceType-Other Sources-1 content type line 63 ObjectType-Editorial-2 ObjectType-Commentary-1 Disclosures of potential conflicts of interest may be found at the end of this article.
ISSN:	1083-7159 1549-490X
DOI:	10.1634/theoncologist.2017-0415